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ABSTRACT
Objectives: The aim of this study was to evaluate the mid-term outcomes of thoracic endovascular aortic repair (TEVAR) of complicated 
type B aortic dissection.
Patients and methods: This retrospective study included a total of 29 consecutive patients (27 males, 2 females; mean age 61.1±11.8 years; 
range, 34 to 80 years) who underwent TEVAR due to complicated type B aortic dissection at our center between March 2015 and December 
2018. All pre-, intra-, and postoperative data were collected. Surgical and discharge notes were reviewed.
Results: Of the patients, 27 had hypertension and seven had coronary artery disease. The mean maximum aortic diameter was 50.5±7.7 mm. 
Suspicion of impending rupture was the most (n=13) associated complication with type B aortic dissection. Six patients (20.7%) had rupture 
and 10 patients (34.5%) had uncontrolled hypertension. The procedure was performed under elective conditions in 18 patients (62.1%) and 
under emergency setting in 11 patients (37.9%). Early mortality was developed in one patient (3.4%) due to low cardiac output syndrome. The 
mean follow-up was 25±11 months. Late mortality occurred in two patients (6.9%) due to lung cancer and sepsis. The overall survival rate was 
86.1±9.8% and freedom from aortic re-intervention was 88.8±7.5% at 50 months.
Conclusion: Our study results show that TEVAR is a safe procedure associated with good postoperative outcomes, and outstanding mid-term 
results in complicated type B aortic dissection.
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Aortic dissection is the most frequent and 
catastrophic manifestation of acute aortic syndrome. 
Stanford type B aortic dissection (TBAD) originates 
in the descending thoracic aorta without retrograde 
extension into the ascending aorta.[1] Type B aortic 
dissection may be classified as uncomplicated or 
complicated. Due to the high mortality rates associated 
with surgery, stable patients with uncomplicated 
type B dissection has traditionally been treated with 
optimal medical therapy (OMT) including aggressive 
anti-hypertensive treatment.[1] Complicated TBAD is 
defined by the presence of at least one of the following: 
aortic rupture or impending rupture, uncontrolled 
hypertension despite full medication, persistent 
abdominal or chest pain, early aortic expansion, and 
malperfusion syndrome involving visceral, renal, or 
extremity ischemia.
Since open surgical repair (OSR) has several 
disadvantages include a long operation time, aortic 
clamping, and neurological complications, thoracic 
endovascular aortic repair (TEVAR) is considered 
as the gold standard for complicated TBAD, 
and current guidelines recommend TEVAR for 
complicated TBAD patients as Class I indications.[2-4] 
The benefits of TEVAR include low-dose heparin 
use, less blood product use, shorter hospital stays, 
avoidance of thoracotomy or sternotomy incision, and 
decreased end-organ ischemia.[5] On the other hand, 
there are several studies maintaining that five-year 
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reintervention rates are much higher in patients 
undergoing TEVAR, compared to OSR.[6,7]
In the present study, we aimed to evaluate the 
mid-term outcomes of TEVAR of complicated TBAD 
patients.
PATIENTS AND METHODS
This retrospective study included a total of 
29 consecutive patients (27 males, 2 females; mean 
age 61.1±11.8 years; range, 34 to 80 years) who 
underwent TEVAR due to complicated TBAD at 
our center between March 2015 and December 2018. 
Patients with TBADs were decided to be complicated 
if one or more of the following complications were 
present: (i) ongoing persistent chest pain, despite 
maximal medical therapy; (ii) radiographic or clinical 
evidence of aortic rupture or impending rupture; 
(iii) malperfusion syndrome involving visceral, 
renal, or extremity ischemia; and (iv) symptomatic 
presentation with an aortic diameter greater than 
5 cm or early aortic expansion. All patients were 
operated by a single surgical team. All pre-, intra-, 
and postoperative data were collected. Surgical and 
discharge notes were reviewed. A written informed 
consent was obtained from each patient. The study 
protocol was approved by the Sakarya University 
Training and Research Hospital Ethics Committee 
(No.71522473/050.01.04/281, Date:23/11/2018). The 
study was conducted in accordance with the principles 
of the Declaration of Helsinki.
Preoperative planning
Initially, all patients were subjected to medical history 
and full physical examination. Electrocardiography, 
chest X-ray, and echocardiography were performed 
for the evaluation of cardiac functions and valve 
pathologies. All patients were evaluated by a 3-mm 
section thoracoabdominal computed tomography (CT) 
angiography with three-dimensional reformatting. 
The CT angiography should be continued from the 
chest to include the abdomen and pelvis too, so that an 
assessment of the iliac arteries can be made to ensure 
suitable access for passage of the stent-graft device. 
The location and size of initial entry and the extent of 
aortic dissection were examined. The size and location 
of the disease segment, presence of calcification or 
thrombus in the vessel wall, presence of malperfusion, 
and the structure of the access arteries were examined. 
Operative techniques
The procedure was performed under general 
anesthesia in an angiography room by the TEVAR 
team including two cardiovascular surgeons and 
an anesthesiologist. Vascular access was obtained 
by a small groin “bikini” incision through the 
unilateral common femoral artery and with the 
installation of a guidewire from the other femoral 
artery. After the administration of systemic 
heparinization (100 IU/kg), wire access was gained 
into the ascending aorta and exchanged for a stiff 
wire to allow tracking of the device. After placement 
of the endograft, angiography was performed with 
power injection and respiratory arrest by anesthesia 
to allow for precise graft positioning. Endograft size 
was selected with 5 to 10% oversize of the calculated 
diameter of the aorta in the proximal non-dissected 
aorta and the true lumen in the distal landing zone. 
We placed a single 15- to 20-cm-long device. When 
needed, a second stent-graft was placed. Completion 
angiography was, then, performed to assess for 
endoleaks; the sheath and device were removed; and 
the arteriotomy was closed. In general, we avoided 
post-deployment angioplasty. Inf lating the aortic 
balloon was performed, only if a large type IA 
proximal endoleak was documented, and only at 
the proximal landing zone. E-vita THORACIC 
3G (JOTEC GmbH, Hechingen, Germany) stent 
grafts were used in 22 patients and Valiant Captivia 
(Medtronic Vascular, Santa Rosa, CA, USA) stent 
grafts in seven patients.
After the procedure, all patients were carefully 
monitored in the cardiac surgery intensive care 
unit (ICU). The mean blood pressure was strictly 
kept around 70 mmHg to prevent retrograde 
aortic dissection or spinal cord ischemic injury. 
In cases involving important aortic side branches 
(e.g. left subclavian artery), we closed the supra-aortic 
branches in the region of the proximal junction of 
the endovascular graft. The subclavian artery was 
covered as needed to obtain an adequate (>2 cm) 
non-dissected landing zone proximal to the entry tear. 
A hybrid approach involving surgical reconstruction 
of the supra-aortic branches and endovascular lesion 
repair was performed.
Follow-up
All patients were postoperatively evaluated with 
CT angiography at one month (first follow-up) and in 
the mid-term (second follow-up). Mid-term follow-up 
was obtained at an average of 25±11 months. The 
aortic diameter was assessed just below the distal end 
of the stent-graft. Complications such as endoleak and 
graft migration were investigated during follow-up 
visits using contrast-enhanced thoracic CT. Follow-up 
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data were analyzed using cardiology and cardiac 
surgery outpatient follow-up notes, primary care and 
institutional computer-based databanks, and telephone 
interviews. Mortality within the first 30 days following 
the procedure was defined as operative mortality.
Statistical analysis
Statistical analysis was performed using the 
IBM SPSS version 25.0 software (IBM Corp., 
Armonk, NY, USA). Continuous variables were 
expressed in mean ± standard deviation (SD), unless 
noted otherwise, while categorical variables were 
expressed in number and frequency. Survival and 
freedom from adverse events were estimated using 
the Kaplan-Meier method.
RESULTS
Of all patients, 27 (93.1%) had hypertension, 
three (10.3%) had diabetes, 14 (48.3%) had chronic 
obstructive pulmonary disease, and seven (24.1%) had 
coronary artery disease (CAD). The mean maximum 
aortic diameter was 50.5±7.7 mm. Suspicion of 
impending rupture was the most (n=13, 44.8%) 
associated complication with TBAD. Six patients 
(20.7%) had rupture and 10 patients (34.5%) had 
uncontrolled hypertension. Baseline demographic and 
clinical characteristics of the patients are summarized 
in Table 1.
The procedure was performed under elective 
conditions in 18 patients (62.1%) and under the 
emergency setting in 11 patients (37.9%). We used 
one graft for each patient, except for one patient in 
whom a second stent graft was placed distally to 
eliminate a type IB endoleak. The mean length of the 
stent graft employed was 194.1±35.1 cm. Supra-aortic 
arch bypass was carried out in one patient (3.4%) 
who was treated with landing Zone 1 TEVAR. No 
immediate open surgical conversions were needed. 
Stent graft and aortic characteristics are listed in 
Table 2. The ostium of the left subclavian artery was 
covered in nine patients (31%) to obtain an adequate 
proximal landing zone. The mean length of ICU stay 
was 1.8±1.5 days and the mean length of ward stay 
was 7±3.4 days.
The early and late postoperative outcomes of all 
patients are presented in Table 3. Early mortality 
was developed in one patient (3.4%) due to low 
cardiac output syndrome who had CAD. One patient 
had a temporary pa raparesis, which resolved within 
15 days. Pulmonary complications occurred in seven 
patients (24.1%). Renal insufficiency defined as serum 
creatinine ≥2.5 mg/dL) occurred in two patients (6.9%) 
and none of these patients required hemodialysis.
The mean follow-up was 25±11 months. Late 
mortality occurred in two patients (6.9%) due to 
lung cancer and sepsis. Cumulative survival analysis 
of patients was assessed by Kaplan-Meier survival 
Table 1. Demographic and clinical characteristics of patients (n=29)




Body mass index (≥30 kg/m2) 1 3.4
Preoperative LVEF (%) 58±7
Smoking history 19 65.5
Associated diseases
Hypertension 27 93.1
Diabetes mellitus  3 10.3
Chronic obstructive pulmonary disease 14 48.3
Peripheral vascular disease 4 13.8
Coronary artery disease 7 24.1
Dialysis-requiring chronic renal failure 1 3.4
Previous cardiac operations 1 3.4
Perioperative aorta diameter (mm) 50.5±7.7
Complications associated with type B dissection
Rupture 6 20.7
Suspected rupture 13 44.8
Malperfusion 2 6.9
Uncontrolled hypertension 10 34.5
Severe refractory pain 9 31
SD: Standard deviation; LVEF: Left ventricle ejection fraction.
Table 2. Operative data (n=29)
Variables n % Mean±SD






Length of the stent graft (mm) 194.1±35.1
Proximal landing zone
Zone 1 1 3.4
Zone 2 8 27.6
Zone 3 15 51.7
Zone 4 5 17.3
Supra-aortic arch bypass 1 3.4
Coverage of LSA 9 31
Stent graft devices
E-vita thoracic 3G 22 75.9
Medtronic valiant captivia delivery system 7 24.1
Intensive care unit stay (day) 1.8±1.5
Hospital stay (day) 7±3.4
SD: Standard deviation; TEVAR: Thoracic endovascular aortic repair; LSA: Left subclavian artery.
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analysis. The overall survival rate was 86.1±9.8% at 
50 months (Figure 1).
Wound healing problem in the femoral incision was 
observed in three patients (10.3%). Type IB endoleak 
developed in three patients (10.3%) at 18, 20, and 24 
months, postoperatively. No additional procedure was 
performed in one patient, while two patients (6.9%) 
had aortic reintervention with TEVAR. The freedom 
from aortic re-intervention rate was 88.8±7.5% at 
50 months (Figure 2). No stent migration, dislocation 
or graft thrombosis was documented in our patients 
postoperatively.
DISCUSSION
In this study, the midterm outcomes of TEVAR for 
complicated TBAD were reported. The early mortality 
was developed in one patient due to CAD. The overall 
survival rate was 86.1±9.8% and freedom from aortic 
re-intervention was 88.8±7.5% at 50 months.
Type B aortic dissection is a life-threating 
disease which needs immediate or delayed treatment. 
Uncomplicated TBAD has classically been treated 
with medical therapy. The role of TEVAR in the 
setting of uncomplicated TBAD is still challenging. 
In the Investigation of Stent Grafts in Aortic 
Dissection (INSTEAD) trial including patients with 
uncomplicated TBAD and comparing combined 
TEVAR and OMT (TEVAR+OMT) with OMT 
alone, there was no significant difference in the two-
year survival rates between the groups.[8] However, 
the INSTEAD-XL trial which was conducted for 
extended for late follow-up showed that TEVAR in 
addition to OMT was beneficial in terms of freedom 
from aortic adverse events.[9]
Aortic rupture, persistent pain, uncontrolled 
hypertension, early aortic expansion and malperfusion 
are the major causes of early mortality in TBAD 
patients.[10] Of note, TBAD patients undergoing 
OSR or TEVAR have a signif icant survival 
advantage over those treated medically alone.[11] As 
OSR for complicated TBAD has been accompanied 
by high morbidity and mortality,[12,13] TEVAR is 
recommended in the treatment for these patients, 
particularly in elderly and comorbid patients.[4] Jonker 
et al.[14] confirmed the beneficial results of TEVAR 
for acute complicated TBAD with an in-hospital 
mortality of 4%, 40% and 33% for TEVAR, OSR, 
and OMT patients, respectively.[14] In our study, the 
in-hospital mortality was seen in only one patient 
(3.4%) due to CAD.
In the present study, two patients were treated 
due to malperfusion involving extremity ischemia. 
In case of malperfusion, coverage on the entry tear 
with the stent graft allows re-expansion of the true 
lumen and increased organ perfusion.[15,16] Coverage 
of the subclavian artery without revascularization 
Table 3. Early and late morbidity and mortality (n=29)
Variables n %
Early (<30 days)
In hospital mortality  1 3.4
Low cardiac output syndrome 1 3.4
Pulmonary complications 7 24.1
Postoperative renal failure* 2 6.9
Healing problem in femoral incision 3 10.3





Endoleak 1A 1 3.4
Endoleak 1B  2 6.9
Graft thrombosis  0 0
Graft migration  0 0
















Figure 1. Kaplan-Meier survival analysis showing overall survival after 
thoracic endovascular aortic repair.
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is generally well-tolerated, but may lead to left arm 
ischemic symptoms in up a minority of patients.[17] 
In our study, the ostium of the left subclavian artery 
was covered in nine patients (31%) to obtain a healthy 
proximal landing zone. In these patients, coverage of 
the left subclavian artery without revascularization 
was well-tolerated without no ischemic symptoms in 
the patients.
Acute kidney injury frequently occurs after 
catheter-based interventional procedures and has been 
shown to increase early morbidity and mortality.[18] 
The incidence of acute kidney injury after TEVAR is 
variable. Ertugay et al.[19] reported renal complications 
in three patients (12%) undergoing TEVAR due 
to acute aortic syndrome, while Karakisi et al.[20] 
reported acute renal failure in two patients (8%). In our 
study, renal insufficiency defined as serum creatinine 
≥2.5 mg/dL occurred in two patients, and none of 
these patients required hemodialysis.
Currently, several meta-analyses have 
demonstrated favorable short and mid-term results 
in patients with complicated TBAD treated with 
TEVAR.[21,22] However, complications with TEVAR, 
such as endoleaks and graft migration, may occur 
more easily than with OSR.[23] In a study, aortic 
reintervention was required in 10.8% (4 of 37) in the 
complicated acute TBAD treated with TEVAR.[10] 
Reinterventions in these patients were due to type A 
aortic dissection in two patients, type I endoleak in one 
patient, and ruptured descending aorta in one patient. 
In our study, aortic reintervention was required in two 
patients (6.9%) due to type IB endoleak. There was 
no graft migration or graft thrombosis in our patients 
during the follow-up period.
Our techniques of groin incision have evolved 
over the years. We used a classic femoral incision 
in the earlier part of our experience. Recently, we 
have favored the “bikini” incision which is more 
comfortable for patients with less complications than 
the conventional technique. In our study, there were 
three patients with wound healing problem in the 
femoral incision and two of them occurred before the 
“bikini” incision.
Nonetheless, this study is limited by its retrospective 
design, small sample size, and mid-term follow-up 
results over a 10-year period. Therefore, further large-
scale, long-term, prospective studies are needed to 
confirm these findings.
In conclusion, our study results suggest that 
TEVAR is a safe procedure associated with good 
postoperative outcomes and outstanding mid-term 
results in complicated TBAD.
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